Cancer stem cells modulate patterns and processes of evolution in cancers by Laplane, Lucie
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The	clonal	evolution	(CE)	model	and	the	cancer	stem	cell	(CSC)	model	are	two	models	of	cancer	that	have	an	













model	 and	 that	 consists	 of	 specifically	 targeting	 the	 CSCs	 during	 cancer	 treatments,	 it	means	 that	 CSCs	 can	
represent	 a	 heterogeneous	 target.	 CSCs	 can	 differ	 both	 synchronically	 (at	 the	 diagnosis	 for	 example)	 and	
diachronically	 (from	 diagnosis	 to	 relapse	 for	 example).	 This	 heterogeneity	 between	 CSCs	 can	 result	 in	 the	
coexistence	of	CSCs	with	various	sensitivities	to	therapies	(e.g.	Meyer	et	al.	2015).	Second,	the	accumulation	of	
new	 mutations	 in	 CSCs	 can	 modify	 their	 properties.	 For	 example,	 additional	 mutations	 could	 lead	 to	 the	









(2009)	 introduced	 a	 framework	 that	 allows	 one	 to	 distinguish	 different	 types	 of	 Darwinian	 populations,	 for	
example	 paradigmatic	 Darwinian	 populations	 in	 which	 evolution	 by	 natural	 selection	 can	 produce	 complex	
adaptations,	i.e.	novel	traits,	versus	marginal	Darwinian	populations	in	which	evolution	by	natural	selection	can	














the	 influence	 of	 CSC	 restriction	 are	 processes	 of	 evolution	 (evolution	 by	 natural	 selection	 versus	 neutral	
evolution,	complex	versus	simple	adaptations)	and	patterns	of	evolution	(linear	versus	branched	evolution).	
The	first	section	shows	that	CSC	restriction	limits	evolution	by	natural	selection	(and	more	generally	CE),	prevents	
complex	 adaptations,	 and	 favors	 drift	 and	 linear	 evolution.	 Scientists	 and	 philosophers	 have	 compared	 CSC	

































in	 some	 cancers,	 non-CSCs	 can	 dedifferentiate	 into	 CSCs	 (e.g.	 Chaffer	 et	 al.	 2013;	 Koren	 et	 al.	 2015;	 Van	
Keymeulen	 et	 al.	 2015;	Medema	 2017).	 Dedifferentiation	 affects	 the	 quantification	 of	 the	 cancer	 cells	 that	
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thus	 fulfill	 the	 minimal	 requirements	 for	 evolution	 by	 natural	 selection;	 they	 are	 populations	 of	 cells	 that	
reproduce	with	some	heritable	variation	in	fitness	(Lewontin	1970;	1978).	Taking	the	CSC	model	 into	account	
makes	 some	 difference	 in	 understanding	 evolution	 in	 cancer	 cells	 because	 it	 indicates	 an	 inequality	 in	 the	
contribution	of	cancer	cells	to	clonal	evolution.	The	CSC	model	distinguishes	two	functionally	distinct	populations	
of	cells,	one	with	a	virtually	unlimited	proliferative	ability	(the	CSCs),	and	the	other	with	a	limited	proliferative	
ability	 (the	 non-CSCs)	 (Fig.	 1b).	 On	 short	 time	 scales	 (days	 to	 weeks)	 this	 functional	 distinction	 makes	 no	












The	 importance	 of	Godfrey-Smith’s	 framework	 for	Germain	was	 that	 it	 allows	 a	more	 precise	 description	 of	
different	types	of	Darwinian	populations	as	functions	of	roughly	measurable	parameters;	the	two	extreme	types	















on	 the	 frequency	 of	 CSCs	 and	 can	 vary	 from	 very	 low	 to	 very	 high,	 which	 differentially	 affects	 CE.	 (d)	 CSC	
restriction	also	depends	on	the	probability	of	dedifferentiation	of	non-CSCs	into	CSCs,	as	mutations	occurring	in	
non-CSCs	 are	 not	 washed	 away	 if	 the	 mutated	 cells	 dedifferentiate	 into	 CSCs.	 High	 or	 low	 probability	 of	
dedifferentiation	will	differentially	affect	CE	
	
Reproductive	 specialization	 refers	 to	 the	 germ/soma	 distinction	 and	 related	 phenomena	 in	 which	 only	 a	
sequestered	part	of	the	individual	can	give	rise	to	a	new	individual	through	sexual	or	asexual	reproduction	(the	
germ	 cells),	 while	 the	 rest	 of	 the	 individual	 cannot	 (the	 somatic	 cells)	 (see	 Godfrey-Smith	 2009,	 p.	 92).	 In	
multicellular	organisms,	reproductive	specialization	partially	suppresses	evolution	by	natural	selection	at	the	cell	
level	by	making	the	somatic	cells	evolutionary	dead-ends	(see	Godfrey-Smith	2009,	p.	101).	Germain	argued	that	
the	 coexistence	 of	 CSCs	 and	 non-CSCs	 in	 cancers	 produces	 a	 reproductive	 specialization	 comparable	 to	 the	
germ/soma	distinction:	non-CSCs	are	unable	to	grow	a	tumor	 like	somatic	cells	are	unable	to	produce	a	new	
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From	 this	 first	 conclusion,	 a	 second	 conclusion	 follows	 in	 Godfrey-Smith’s	 framework:	 the	 less	 paradigmatic	
cancer	cell	populations	are,	 the	 less	 likely	complex	adaptations	are	 to	occur	because	paradigmatic	Darwinian	
populations	are	characterized	as	those	in	which	natural	selection	can	explain	the	origin	of	novel	traits	(complex	























































discussed	 in	 Gao	 et	 al.	 	 (2016).	 Markowetz	 (2016)	 suggested	 that	 saltationist	 theories	 such	 as	 the	 hopeful	
monsters	theory	of	Richard	Goldschmidt	might	be	more	relevant	in	cancers.	




impact	whether	 cancers	 follow	a	pattern	of	neutral	 evolution?	A	model	developed	by	Sottoriva	et	 al.	 (2010)	
suggests	as	much.	In	this	model,	Sottoriva	and	colleagues	observed	that	CE	was	impacted	in	two	ways	when	they	
factored	in	the	CSC	model	(i.e.	by	distinguishing	two	functionally	distinct	populations	of	cancer	cells,	CSCs	and	
non-CSCs).	 First,	 as	 already	discussed	 in	 section	1.1,	CSCs	 repress	CE	by	making	 the	acquisition	of	mutations	
slower.	 Second,	 they	 observed	 a	 different	 clonal	 expansion	 process.	When	 the	 CSC	model	 is	 not	 taken	 into	
account,	a	small	number	of	the	occurring	mutations	were	selected	for	and	invaded	large	portions	of	the	cancer	
cell	population.	In	contrast,	the	implementation	of	the	CSC	model	resulted	in	the	persistence	of	a	large	proportion	






higher	 CSC	 restriction	 in	 the	 cancers	 that	 fitted	 the	 neutral	model	 in	Williams	 et	 al.	 (2016).	 To	 answer	 this	
question,	one	would	have	to	align	the	analysis	of	neutral	evolution	from	whole	genome	sequencing	data	with	










                                                   
6	 Whether	 a	 first	 stage	 of	 evolution	 by	 natural	 selection	 precedes	 neutral	 evolution	 is	 a	 matter	 of	 debate	
(Martincorena	et	al.	2015;	Simons	2016).	




one	 after	 another	 (Fig.	 5a).	 In	 this	 pattern	 of	 CE,	 intratumoral	 heterogeneity	 (ITH)	 is	 diachronic	 rather	 than	











mutations	 with	 each	 new	 clone	 outcompeting	 the	 previous	 so	 that	 subclones	 accumulating	 new	mutations	
succeed	one	another.	(b)	When	selective	sweeps	are	incomplete	and	former	subclones	persist	without	giving	rise	
to	new	subclones,	the	CS	is	linear	heterogeneous.	(c)	When	former	subclones	accumulate	mutations	and	give	rise	







mutations	and	 the	probability	of	propagation	of	 the	mutations.	 If	mutations	are	 less	 frequent	and	propagate	
more	easily	in	a	smaller	population,	then	there	is	a	higher	chance	that	the	second	mutation	occurs	on	top	of	the	










CE.	Higher	CSC	 restriction	 should	 thus	 favor	 linear	CE,	whereas	 a	 loss	 of	 CSC	 restriction	by	 an	 increased	CSC	




been	reported	are	 in	blood	cancers	(supplementary	table	1,	grey	 lines),	which	are	characterized	by	a	 low	CSC	
frequency	and	no	dedifferentiation,	thus	a	high	CSC	restriction.	The	only	exception	comes	from	Shain	et	al.	(2015)	




can	dedifferentiate	and	CSC	 frequency	 is	higher,	 such	as	breast	 cancers,	 colon	cancers,	 advanced	melanoma,	
brain	 cancers,	 osteosarcoma,	 and	 pancreatic	 cancers,	 follow	 branched	 patterns	 of	 evolution	 (supplementary	
table	1).	The	second	kind	of	evidence	comes	from	patterns	of	accumulation	of	mutations	in	normal	tissues	(i.e.	
without	any	overt	cancer	being	diagnosed).	Presence	of	mutations	usually	associated	with	cancers	without	overt	
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the	 fidelity	 of	 heredity	 largely	 depends	 on	 the	 quantity	 of	mutations,	which	 is	 highly	 variable.	 For	 example,	
comparing	30	cancer	types,	Alexandrov	et	al.	(2013)	reported	a	mutational	load	ranging	from	about	0.001/Mb	to	














labor	 that	has	massive	 impacts	on	 the	 long-term	 fitness	of	 the	 cells.	But	 this	 analogy	has	 several	 limitations.	
Reproductive	 specialization	 refers	 to	 the	germ/soma	distinction,	or	 equivalent	phenomena.	 It	 relies	on	 three	
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into	CSCs,	the	question	becomes	whether	CSC	restriction	(CSC	frequency	and	probability	of	dedifferentiation)	







equates	 to	 the	 degree	 of	 reproductive	 specialization.	 But	 CSC	 restriction	 also	 depends	 on	 the	 probability	 of	
dedifferentiation,	and	when	non-CSCs	can	dedifferentiate	into	CSCs,	then	there	is	no	reproductive	specialization,	
but	rather	a	bottleneck.	However,	as	the	degree	of	bottleneckishness	is	stable	(one	cell,	the	CSC),	it	is	unlikely	to	





















                                                   
8	I	am	very	grateful	to	both	anonymous	reviewers	for	the	thorough	discussion	that	has	lead	to	this	version	of	the	
argument.		














intrinsic	properties	hangs	upon	 the	 relative	contribution	of	 intrinsic	and	extrinsic	 factors	 in	 stemness.	Finally,	
dependence	of	fitness	on	intrinsic	properties	is	high	in	cases	where	stemness	is	a	categorical	property	because	















of	clones	with	no	clear	survival	benefit	 (see	section	1.2).9	More	generally,	 the	arguments	 that	CSC	restriction	
represses	 CE,	 favors	 drift,	 prevents	 complex	 adaptations,	 and	 favors	 linear	 evolution,	 could	 be	 reduced	 to	 a	
question	 of	 effective	 population	 size,	 if	 the	 probability	 of	 dedifferentiation	 is	 null.	 But	 if	 non-CSCs	 can	
dedifferentiate	 into	 CSCs	 at	 any	 time,	 then	 the	 actual	 CSC	 frequency	 poorly	 represents	 the	 cells	 that	 can	
                                                   
9	The	 idea	 that	drift	dominates	 selection	 in	 small	populations	has	been	debated,	 see	 for	example	 the	 recent	
debate	between	Clatterbuck,	Sober	and	Lewontin	(2013)	and	Brandon	and	Fleming	(2014).	










of	 evolution,	 and	 in	 particular	 that	 it	 can	 favor	 linear	 or	 branched	 evolution.	 Scientists	 regularly	 investigate	
whether	CE	is	linear	or	branched	but	give	limited	attention	to	the	difference	it	makes.	Why	should	we	care	about	
the	 impact	 of	 CSC	 restriction	 on	 linear	 or	 branched	 evolution?	 In	 this	 section,	 I	 argue	 that	 the	 relationship	
between	CSC	 restriction	and	patterns	of	CE	 is	worth	exploring	 for	 the	biomedical	 sciences,	 first,	because	 the	
patterns	of	CE	can	inform	us	about	CSC	restriction,	and	in	particular	about	the	probability	of	dedifferentiation	





success	 in	that	environment.	 In	cases	of	neutral	evolution,	the	bigger	subclones	are	the	oldest.	 In	addition	to	
these	inferences,	I	have	argued	in	this	paper	that	the	pattern	of	CE—linear	or	branched—is,	at	least	in	part,	a	
function	of	CSC	restriction.	If	I	am	right,	then	reconstruction	of	the	CE	could	be	informative	about	CSC	restriction.	




dedifferentiation	 is	 high	 or	 low).	 This	 is	 far	 from	 trivial	 given	 that	 the	 current	 technologies	 allow	 far	 better	
approximations	of	CE	patterns	and	of	CSC	frequencies	than	of	the	probability	of	dedifferentiation.	
3.2.	From	CSC	restriction	to	CE	patterns:	therapeutic	consequences	
What	 difference	 does	 it	 make	 if	 CE	 is	 linear	 or	 branched?	 Is	 one	 or	 the	 other	 better	 for	 the	 patients?	 The	
immediate	 relevance	of	distinguishing	CE	patterns	 is	 that	 the	coexistence	of	multiple	 subclones	 is	a	cause	of	
therapy	resistance.	The	more	subclones	there	are,	the	greater	the	risk	of	therapy	resistance.	If	my	hypothesis	
that	a	higher	CSC	restriction	should	favor	a	more	linear	and	simpler	pattern	of	CE	is	right,	then	patients	would	
benefit	 from	 any	 complementary	 therapies	 that	 can	 increase	 CSC	 restriction.	 Opportunities	 to	 control	 CSC	
restriction	are	emerging.	The	most	recent	examples	are	Cimmino	et	al.	(2017)	and	Agathocleous	et	al.	(2017),	
who	showed	that	vitamin	C	regulates	the	frequency	of	normal	or	malignant	hematopoietic	stem	cells.		





But	HMAs	have	 also	been	used	 in	 a	 very	different	 context,	 unrelated	 to	 cancer,	 to	 induce	 cell	 plasticity	 and	
dedifferentiation	(e.g.	Mikkelsen	et	al.	2008;	Chandrakanthan	et	al.	2016).	Some	studies	also	suggest	that	HMAs	
can	decrease	stem	cell	restriction	in	the	normal	hematopoietic	system,	either	by	increasing	their	frequency	or	by	












the	 impact	of	 the	CSC	model	 on	CE	has	been	poorly	 explored.	 This	 article	 shows	 that	CSC	 restriction,	which	







A	 loss	of	CSC	 restriction	 (higher	CSC	 frequency	and/or	higher	probability	of	dedifferentiation)	during	disease	
progression	will	thus	favor	more	adaptability,	making	the	inclusion	of	CSC	restriction	into	the	CE	model	highly	
relevant	for	biomedical	research.	
Incorporating	 CSC	 restriction	 into	 the	 CE	 model	 faces	 several	 difficulties,	 opening	 perspectives	 for	 further	
philosophical	 and	 biological	 research.	 First,	within	 current	 experimental	 limitations,	 it	 is	 difficult	 to	 properly	
quantify	the	number	of	CSCs	and	the	probability	of	dedifferentiation	within	a	cancer	at	any	given	time.	Thus	CSC	
restriction	 can	only	be	 roughly	estimated.	Current	 improvements	 in	 lineage	 tracing	 technologies	will	 provide	
great	help.	Estimation	of	the	probability	of	dedifferentiation	of	non-CSCs	into	CSCs	is	also	becoming	an	urgent	
need	that	remains	too	poorly	addressed.	












we	 act	 on	 CSC	 restriction	 in	 order	 to	 limit	 CE	 and	 disease	 progression?	 To	 answer	 this	 question	 requires	
investigating	the	two	factors	of	CSC	restriction:	CSC	frequency	and	non-CSC	dedifferentiation.	What	causes	an	
increase	 in	the	frequency	of	CSCs	within	a	given	cancer,	and	how	can	this	 increase	 in	the	number	of	CSCs	be	
avoided	or	reduced?	What	induces	dedifferentiation	of	non-CSCs	into	CSCs	and	how	can	we	prevent	it?	These	
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